CTLA4 and melanoma: Another humanized anti-CTLA-4 antibody, tremelimumab obtained durable responses in phase I/II clinical studies with melanoma but fell short in Phase III randomized clinical trial (Boussiotis, 2014; Topalian et al., 2014; Deng et al., 2015; Sznol and Longo, 2015; Kataoka et al., 2016).